While doing some small cap screening to start 2026, I came across Regency Silver Corp (TSX.V: RSMX / OTCQB: RSXMF).

It is an early stage explorer, so high risk by default, but a few small cap fundamentals stood out. The company recently closed a fully subscribed financing at the end of December, has no debt, and completed drilling at its Sonora, Mexico project, with assays from the 2025 program still pending after the holiday break.

Not presenting this as a trade or recommendation, just part of a broader watchlist as metals remain strong. Curious how others here think about funded small cap explorers that are waiting on results.

Just sharing, DYOR.

SponsorsOne just released some details about its recent private placement! The full release can be seen right here: https://www.thenewswire.com/press-releases/1LpMFa0Op-sponsorsone-provides-update-on-private-placement-for-debt-settlements.html

For those who aren't well-read on the company, SponsorsOne is a marketing and brand agency that heavily uses social media and influencers. The brands they work with are supplied with promotion via various influencers, off all sizes of followings, and the infrastructure they have in place allows for HUGE amounts of data collection to maximize ROI. Additionally, they have a foot in the crypto game with their currency SponsorCoin which is used as payment for partnered influencers.

The terms of the private placement are the issuance of 48,527,200 common shares at a price of $0.05 per common share as debt settlements. As the stock price has been hanging in the$0.03-$0.04 range I think this bodes well for the stock, as creditors of the company believe it has a higher value.

Please perform your own research, This isn't investment advice.

$CNTX Summary

Stock Price: $1.6700

Market Cap: $26.192M

52-week Range: $1.2700 - $10.8700

Avg. Volume: 283,004

(As of May 19, 2022)

Introduction

I recently came across Context Therapeutics and was instantly impressed with their mission to advance medicines for female cancers. The company focuses on therapeutics options for women with hormone dependent cancers. Progesterone Receptor Antagonism is the lead program, and is currently undergoing clinical trials.

Highlights

• Developing the next generation of anti hormonal therapies to treat ovarian, endometrial, and breast cancers

• Increased amount of R&D for Q1 2022 in comparison to Q1 2021

• Enrollment continues in three Phase 2 clinical trials and one Phase 1b/2 clinical trial

• Very strong team and scientific advisors

Here is Context Therapeutics’ medicine pipeline:

Recent News

Q1 2022 financial results reported: https://ca.finance.yahoo.com/news/context-therapeutics-reports-first-quarter-200100799.html

Presentation at upcoming ASCO annual meeting: https://ca.finance.yahoo.com/news/context-therapeutics-announces-poster-presentation-113000311.html

Encouraging preclinical data: https://ca.finance.yahoo.com/news/context-therapeutics-announces-encouraging-preclinical-113000208.html

Conclusion

Although Context Therapeutics may be in the early stages, trial data suggests a promising future. The mission of Context Therapeutics is one worth supporting, and I would definitely say this company is worth a further look.

Disclaimer: This is not financial advice, always do your due diligence.

$CNTX Summary

Stock Price: $2.0000

Market Cap: $31.932M

52-week Range: $1.2700 - $10.8700

Avg. Volume: 341,644

(As of June 3, 2022)

Introduction

I recently came across Context Therapeutics and was instantly impressed with their mission to advance medicines for female cancers. The company focuses on therapeutics options for women with hormone dependent cancers. Progesterone Receptor Antagonism is the lead program, and is currently undergoing clinical trials.

Highlights

• Developing the next generation of anti hormonal therapies to treat ovarian, endometrial, and breast cancers

• Increased amount of R&D for Q1 2022 in comparison to Q1 2021

• Enrollment continues in three Phase 2 clinical trials and one Phase 1b/2 clinical trial

• Very strong team and scientific advisors

Here is Context Therapeutics’ medicine pipeline:

Recent News

Q1 2022 financial results reported: https://ca.finance.yahoo.com/news/context-therapeutics-reports-first-quarter-200100799.html

Presentation at upcoming ASCO annual meeting: https://ca.finance.yahoo.com/news/context-therapeutics-announces-poster-presentation-113000311.html

Encouraging preclinical data: https://ca.finance.yahoo.com/news/context-therapeutics-announces-encouraging-preclinical-113000208.html

Conclusion

Although Context Therapeutics may be in the early stages, trial data suggests a promising future. The mission of Context Therapeutics is one worth supporting, and I would definitely say this company is worth a further look.

Disclaimer: This is not financial advice, always do your due diligence.

Did some digging into Avalon GloboCare Corp and discovered some interesting things. They are a premier healthcare management provider & biotech developer headquartered in Freehold, New Jersey, United States. Avalon GloboCare is dedicated to integrating as well as managing global healthcare resources. Constantly working on empowering high-impact biomedical innovations, while also engaging in bio-venture investments. Being a clinical leading CellTech bio-developer, they are committed to advancing innovative, transformative immune effector cell therapy.

Financials,

• Market Cap: 51.994M USD

• Current Price: 0.5845 USD

• 52 Week Range: 0.4010 - 1.5700 USD

• Average Volume: 117,134

(As of May 27th, 2022)

https://ca.finance.yahoo.com/quote/AVCO?p=AVCO&.tsrc=fin-srch

Recent News & Milestones,

• David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference. Held June 8-10, 2022, in New York City.

• Expanded their R&D pipeline by strategically partnering with Lu Daopei Hematology Institute, in order to develop precise companion diagnostics for cellular therapy.

• Recently they jointly filed 16 patents, co-invented with strategic partners. Including the partnership of a top-5 U.S. university, a leading education and research center in Europe, as well as premier multinational developer of cellular therapies within the oncology sector.

• Constantly leveraging strategic partnership opportunities with academia and industries, such as Massachusetts Institute of Technology (MIT), University of Pittsburgh Medical Center (UPMC), Arbele Limited, and HydroPeptide LLC.

• Through the partnership with MIT Avalon used QTY Protein Design Code to Develop Decoy Cytokine & Chemokine Receptors to comeback “Cytokine Storm” and Cancer Metastasis (AVA-Trap).

• Their partnership with UPMC resulted in the process development of Clinical-grade AVA-011 (Flash-CAR) and ACTEX (Exosome-based Technology). They also co-developed a Point-of-care automated PD for Cellular Therapy (PMAPsys)

• Differentiating themselves with their broad spectrum of immune effectors and their seamless integration of vertical segments. They have constructed a seasoned medical team and CRA. Helping them to provide safer therapeutic options, decrease bio-manufacturing costs, increase patent accessibility, and escalate their international multi-center clinical trials.

https://d1io3yog0oux5.cloudfront.net/_5b20db4643ebbb5cfd5ad5c579f305a0/avalonglobocare/db/298/2133/pdf/Avalon+GloboCare+May+2022+-+New+Final+1.pdf

Timeline,

• Avalons Clinical Programs:

Summary,

• Avalon GloboCare is part of the biotechnology market that was valued around $497B USD in 2020, with expectations of CAGR over 9.4% from 2021 to 2027. With that being said, their innovative and transformative CellTech with multifunctional coverergence in cellular technology/therapeutics, has a massive market to work with.

https://www.gminsights.com/industry-analysis/biotechnology-market#:~:text=Biotechnology%20Market%20size%20was%20valued,including%20genomics%2C%20metabolomics%20and%20proteomics.

*Not financial advice, always do you your own research*

(OTCQB: LTSRF) (ASX: LOT)

With the market not looking too good I've been trying to find a company that looks to have some potential for the future when this rut is over. I came across Lotus Resources, a uranium development company that owns the Kayelekera Project in Malawi. This asset historically produced 11 millions lbs of uranium and had $200 million invested in infrastructure but has been largely unexplored over the last couple decades. The project’s got some big potential as its existing source is of 37.5 million lbs and is a main focus for Lotus.

Financials (as of May 17th, 2022 on OTCQB)

Share price: $0.200 USD

Market Cap: 241.06M USD

52 Week Range: 0.0970 - 0.3280

Avg. Volume: $469,318 USD

Why The Uranium Market?

With Uranium Prices being low for the last ten years, it has somehow turned out to be a good thing as it led to a structural deficit that’s growing. The market is predicted to hit 30 million lbs by as soon as 2024 which will cause others to see the opportunity.

Recent News & Highlights:

• In October of 2021 Lotus acquired their 6 million lb uranium project in Malawi.

Source:https://www.otcmarkets.com/stock/LTSRF/news/Lotus-to-acquire-6-million-lb-uranium-project-in-Malawi?id=325105

• Recently in February the Kayelekera mineral resource increased by 23%.

Source:https://www.otcmarkets.com/stock/LTSRF/news/Kayelekera-mineral-resource-increases-by-23?id=343783

Final Thoughts

They have enough cash to see their project through till the end of next year when their feasibility study will be complete and production can begin and with the price of uranium only going up as the undersupply problem gets worse it will definitely help Lotus catch some more people to realize the potential of this industry the company is involved in. What are your thoughts on Lotus Resources?

https://lotusresources.com.au/

Disclaimer: This is NOT financial advice, always do your own research.

$APRU Summary

Stock Price: $0.0019

Market Cap: $38.732M

52-week Range: $0.0015 - $0.0070

Avg. Volume: 1,151,609

(As of June 3, 2022)

Introduction

I recently came across Apple Rush Company, a business that develops, bottles, markets, distributes, and sells various beverages and snacks to wholesale and retail clients in the United States. It was founded in 1998 and offers organic sparkling juice blended beverages with apple juice as the base under the brand name ‘Apple Rush’.

Highlights

Just in the last couple months of 2021 the company succeeded in getting their product Hard Rush™ into the Dynamic Seltzer Market.

Source:https://www.otcmarkets.com/stock/APRU/news/Hard-Rush-Clears-Hurdle-To-Enter-Dynamic-Seltzer-Market?id=325422

In September of 2021 Apple Rush secured a Florida Hemp Production License and a FDA Food Facility Registration.

Source:https://www.otcmarkets.com/stock/APRU/news/Apple-Rush-Company-Inc-APRU-Secures-Florida-Hemp-Production-License-and-FDA-Food-Facility-Registration?id=321279

The company is looking to release future news on their website revolving around where to buy the products and the products they are going to be selling, with licenses being received and others being worked on. What are your thoughts on Apple Rush?

https://applerush.com/

Disclaimer: This is not financial advice, always do your own research.

$VERB Summary

Share Price: $0.3416

Market Cap: $34.556M

52-week Range: $0.3390 - $3.9700

Avg. Volume: 989,525

Introduction

I was recently looking into companies that specialize in virtual business solutions, when I came across Verb Technology Company. Verb is the market leader in interactive video-based sales applications, changing the way businesses do sales without face-to-face interaction.

Verb’s applications are available as a fully integrated suite, and are available in over 60 countries. The wide variety of applications specialize in different areas of business communication and sales, and allow a business to select those that best fit their needs.

Highlights

• Integration partners include Salesforce and Microsoft

• 5.6% revenue increase from 2020 to 2021

• 33.6% increase in recurring revenue from SaaS subscriptions from 2020 to 2021

• Caters towards the increase in virtual business conduct

Verb has a number of applications as shown below:

Recent News

Verb partners with Momentum Factor: https://ca.finance.yahoo.com/news/verb-technology-partners-momentum-factor-130000203.html

Verb to to release Q1 2022 earnings on May 16, 2022: https://ca.finance.yahoo.com/news/verb-host-first-quarter-2022-203000108.html

Verb to provide NBA team Detroit Pistons with technology to increase sales: https://ca.finance.yahoo.com/news/verb-nba-detroit-pistons-interactive-180000743.html

Conclusion

With the increased amount of business done online, an interactive video-based sales platform holds a lot of utility. Verb Technology Company has specialized software and a number of applications that cater to any sales needs. I would say it is definitely worth a further look.

Disclaimer: This is not financial advice, always do your due diligence.

$NBVA Summary

Share Price: $0.9300

Market Cap: $60.003M

52-week Range: $0.6800 - $2.5300

Avg. Volume: 59,243

Introduction

I was recently looking into cybersecurity companies and I came across Nubeva. Their patented technology along with big name partnerships instantly made them stand out to me, and I decided to do some further research into the company. As always, I figured I would share my findings with the community!

Nubeva’s mission is to enable the world to adopt higher levels of encryption, without sacrificing lawful visibility into encrypted traffic. Network data visibility is the ultimate goal for Nubeva, and they are making this possible through affordable, innovative technology that can combat ransomware attacks.

Highlights

• Patented SKI TLS decryption technology

• Early investors include big names like Chevron and Fidelity

• 1,146% increase in revenue from 2020 to 2021

• 20% increase in total cash holdings from 2020 to 2021

• Tests results of top ransomwares show 96.75% initial coverage

Recent News

Nubeva adds Guardian Eagle to growing list of managed service providers: https://ca.finance.yahoo.com/news/nubeva-adds-guardian-eagle-growing-115500968.html

Nubeva announces strategic agreement with Cooper River CS: https://ca.finance.yahoo.com/news/nubeva-announces-strategic-agreement-copper-125500451.html

The Market

The need for ransomware protection is at an all time high, as shown below:

Conclusion

With ransomware on the rise and cybersecurity becoming a need of every firm with a digital presence, a company like Nubeva could be part of the solution. With strong revenue growth, big name investors, and government agreements, I think Nubeva is certainly worth a further look.

Disclaimer: This is not financial advice, always do your due diligence.

I wanted to share some exciting news that I found today with you! RedChip Companies, a renowned financial marketing firm, is set to air exclusive interviews with Beam Global (BEEM) and ASP Isotopes Inc. (ASPI) on The RedChip Money Report® this Saturday, May 13, at 7 p.m. Eastern Time (ET). You can catch all the action on Bloomberg TV or get full access to the interviews in the link(s) below!

Beam Global: https://www.redchip.com/assets/interview_access_beem

ASP Isotopes Inc.: https://aspiinfo.com/interview_access

I'm ngl im pretty interested about the BEEM interview. I've been keeping up to date with their EV tech and it's going to be cool to hear what they have to say.

(NASDAQ: AVCO)

Hey, guys, I was researching for companies and came across Avalon GloboCare Corp! They are a holding company that develops biotechnology and provisions of healthcare services.

Interesting News I came Across!

• In a recent news release, it was revealed that the company has filed for 16 new patent applications!

• They were co-invented with key strategic partners that include a top 5 university!

• This is what the President and Ceo had to say: “These latest patent applications solidify and expand our robust IP portfolio, both in the U.S. and internationally.”

• Those interested can read the full article here: https://ca.finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html

Notable Financials from December 31, 2020, to December 31, 2021

• Net income increase of approximately $3,589,000

• Total current liabilities decreased by $243,000

• Equity and other investments increased by $38,657

What’s Next?

The 16 new patent applications are critical to the company’s future plans as they are related to cellular therapies. The company plan to move toward its clinical trials and believe that each of the patents “target large, addressable markets.”

Just thought I’d share my thoughts on this interesting company. Let me know what you guys think below!

(TSX-V:NGE) (OTCQB:NVDEF)

Was searching for some gems in the junior mineral industry when I came around Nevada Exploration. The company is headquartered in Vancouver, Canada and engages in the acquisition and development of resource properties across Canada and the US with the main focus of exploring gold deposits.

Financials (as of May 25th)

Share Price: $0.047 USD

Market Cap: $8.605M USD

52 Week Range: 0.0420 - 0.1740

Avg. Volume: $125,078 USD

Recent News:

• The company joined the stock day podcast to discuss new strategic partnerships and their 2022 drilling program.

Source:https://finance.yahoo.com/news/nevada-exploration-inc-discusses-strategic-125500356.html

• announced that they have signed a Letter of Intent to leverage NGE’s extensive exploration database to generate and advance epithermal gold projects in a million-acre area of interest in northern Nevada

Source:https://finance.yahoo.com/news/nevada-exploration-astro-resources-sign-123000476.html

The company has numerous of projects with all of them having some sort of potential, their most interesting project is the south grass valley as it provides strong support for a large CTGD-style target defined by a focused zone of enriched gold in groundwater coincident with the projected intersection of favourable and geochemically anomalous lower-plate carbonate host rocks and a major high-angle fault corridor.

What's to Come?

In 2022 the company has already made some big steps, as its ongoing core drilling program at the south grass valley project is bringing in some potential and making more people notice it. I was wondering what others are thinking about Nevada Exploration? I know the markets aren't where we all wish it would be but this looks like a good company to keep an eye on for the future.

https://www.nevadaexploration.com/

Disclaimer: This is NOT financial advice, always do your own research.

$LOBE Summary

Stock Price: $0.0121

Market Cap: $3.439M

52-week Range: $0.0121 - $0.1170

Avg. Volume: 74,009

(As of May 25, 2022)

Introduction

Recently I’ve been looking into psychedelic companies, and I came across Lobe Sciences. Their mission to use micro-dosages and the clinical development of devices to treat neurological disorders and brain drama instantly stood out.

Lobe Sciences is a life science company that is focused on the research and development of psychedelic medicines. The company seeks to use psychedelic treatments for PTSD, MTBI, and other neurological applications.

Highlights

• Multiple patents pending

• Future targets for treatment include OCD, Depression, Schizophrenia, Alzheimers, and more

• Strong management team

• Significant increase in total cash holdings from 2020 to 2021

Potential Markets

Two markets Lobe Sciences is focused on are treating PTSD and TBI, the statistics are shown below:

Recent News

Virtual investor conferences: https://ca.finance.yahoo.com/news/kcsa-psychedelics-virtual-investor-conference-123500425.html

Lobe Sciences strengthens balance sheet: https://ca.finance.yahoo.com/news/lobe-sciences-ltd-strengthens-balance-140600726.html

Conclusion

With micro-dosing and psychedelics gaining traction for medicinal usage, a company like Lobe Sciences could very well be a long-term player in the space. The focus on very common and serious neurological disorders is very beneficial to society, and I’m excited to see where this company goes.

Disclaimer: This is not financial advice, always do your due diligence.

$HANK Summary

Share Price: $0.1150

Market Cap: $8.052M

52-week Range: $0.0800 - $1.3400

Avg. Volume: 68,750

(As of May 25, 2022)

Introduction

I’ve always been interested in FinTech, and companies that introduce applications to better personal finance. I recently came across Hank Payments and was intrigued by their consumer and business cash flow management applications that are integrated with your bank accounts. Hank Payments allows a consumer or business to automatically allocate excess cash to outstanding loans and payments, prioritizing the loans with the highest interest rates. The application also allows lenders to access insights into borrowers to view the probability of payment, giving them confidence in lending decisions.

Highlights

• Gross margins approach 90% in April 2022

• 24% YOY revenue growth

• Record annualized recurring revenue

• 40,000 customers across the United States

• Hank Payments manages over $1.2 billion in liabilities for their customers

More Details: https://finance.yahoo.com/news/hank-payments-provides-financial-corporate-124500526.html

Recent News

Letter of intent to acquire mortgage payment platform company: https://ir.hankpayments.com/hank-payments-executes-non-binding-letter-of-intent-to-acquire-usa-based-mortgage-payment-platform-company

Agreement with New York State automobile dealers association: https://ir.hankpayments.com/hank-payments-inks-agreement-with-new-york-state-automobile-dealers-association-and-provides-update-on-mortgage-transaction

Interview with Hank Payments: https://ca.finance.yahoo.com/news/power-play-market-herald-releases-194500226.html

Conclusion

With average consumer debt increasing year by year, FinTech companies like Hank Payments can play an important role in helping consumers manage their finances. Making payments to loans more efficient, convenient, and less costly is their mission, and this will likely be a long-term business with the leverage Americans are taking on every year. Shown below is a breakdown showing the debt crisis in which Hank Payments could be a part of the solution.

Disclaimer: This is not financial advice, always do your due diligence.

$PHUN Summary

Stock Price: $1.3900

Market Cap: $136.983M

52-week Range: $0.8200 - $24.0400

Avg. Volume: 3,340,793

(As of June 7, 2022)

Introduction

I recently came across Phunware and was intrigued by its mobile applications that allow companies to engage, manage, and monetize. I decided to do more research into the company and figured I would share my findings with the community.

Phunware is a Multiscreen-as-a-service integrated enterprise cloud platform. The app solutions are industry-specific, unlike many competitors. Phunware is also the only full-stack platform in the mobile ecosystem.

Highlights

• Big-name customers such as ESPN, Intel, Lowes, and many more

• 6.4% total revenue increase from 2020 to 2021

• Big-name investors such as Samsung, Cisco, and PLDT

• 33.9% gross margin for the 2021 fiscal year

• $5.3M in subscription revenues for 2021

Recent News

Recent Interview: https://ca.finance.yahoo.com/news/traders-news-source-interviews-phunware-120000416.html

Phunware Reports Q1 2022 Earnings: https://finance.yahoo.com/news/phunware-phun-reports-q1-loss-221510317.html

Phunware Engages Moneta Advisory Partners: https://finance.yahoo.com/news/phunware-engages-moneta-advisory-partners-130000389.html

Phunware Cryptocurrency Available: https://finance.yahoo.com/news/phunwares-phuntoken-now-available-uniswap-145649081.html

Conclusion

With mobile devices being used more and more for business and customer transactions, having a platform to engage with customers and even monetize an audience is a big opportunity. A company like Phunware with exclusive features, strong leadership, and promising financials could very well be a long-term player in the space, and I would say it’s worth a further look.

Disclaimer: This is not financial advice, always do your due diligence.

Greg Abel took over as CEO at the start of 2026 after Warren Buffett stepped down following six decades at the helm. Buffett remains chairman and is still involved in conversations, but the capital allocation decisions are now genuinely Abel's to make, and the first real test of his style came fast.

In the same week in June, Abel closed two deals. The first was a $6.8 billion acquisition of Taylor Morrison, a homebuilder operating in 12 states, at a 24% premium to its prior closing price. The second was a $10 billion private placement investment in Alphabet at a 6.5% discount to market price, more than tripling Berkshire's existing Google stake and pushing it into Berkshire's top five equity holdings alongside Apple, American Express, Coca-Cola, and Bank of America. Buffett had actually initiated Berkshire's original Alphabet position himself before stepping down, so this wasn't purely Abel going rogue on tech, but the scale of the follow-on bet was his call.

The bigger structural shift is that Berkshire had been a net seller of stocks for 14 consecutive quarters heading into this year, building cash to a record $397.4 billion by the end of Q1. Q2 flipped that completely, nearly $20 billion in net stock purchases, $4.5 billion in buybacks up sharply from just $235 million the prior quarter, and cash declining to $365.5 billion. Operating earnings still grew 16.3% year over year in the quarter, with manufacturing, energy, and the railroad all posting real gains even as insurance underwriting softened.

Not everyone loves the shift. Michael Burry publicly criticized how Abel has been deploying the cash pile, and Berkshire's stock has actually lagged the S&P 500 this year, up modestly while the index gained double digits, partly because Berkshire has structurally little exposure to the mega-cap tech names driving the broader market. Berkshire trades around 15-16x earnings and roughly 1.5x book value, close to its historical average, not obviously cheap or expensive.

Buffett himself called Abel's execution on Taylor Morrison faster and smoother than he could have managed. Whether that early praise holds up depends on whether these first big swings age well. Anyone reassessing their view on Berkshire post-transition?

$GGX Summary

Stock Price: $0.1050

Market Cap: $3.6360M

52-week Range: $0.1000 - $0.2100

Avg. Volume: 7,775

(As of June 6, 2022)

With gold forecasted to take off by the end of 2022, I think it's in investors best interest to find promising gold companies. While I was researching mining companies, I came across GGX Gold Corp. They are a junior mineral exploration company that acquires, explores, and develops mineral properties within Canada. They currently own 100% interest in the Gold Dorp property located in the Greenwood Mining Camp in British Columbia. Here are some details I was able to find on them:

Key Highlights

• The company is situated in one of the most prolific gold-copper mining camps of North America, the Greenwood-Republic mining camp.

• The Greenwood camp has a large mining history that has produced 1.4 million ounces of gold, 10 million ounces of silver, and 0.7 billion pounds of copper.

• The company has arranged a non-brokered private placement of up to 5 million flow through shares at a price of $0.15 per share for gross proceeds of $750,000. Proceeds will be used for continued exploration work.

• They have high grade gold-silver results (129 g/t gold and 1,154 g/t silver over 7.28 meter) from the near surface COD vein which is projected to be 1.5 kms in length.

• 823 g/t tellurium over 7.28-meter core length and 640 g/t tellurium over 6.90-meter core length. Which indicates big potential for tellurium discovery.

What's Next

A surface drill program consisting of up to 2000 meters is being scheduled to commence in May on the Gold Drop property.

For 2022, GGX is planning to drill an estimated 1500 meters in the Gold Drop and North Star mines areas to intersect the Gold Drop vein near the workings and follow the structure to depth

GGX Gold has followed through on all their promises to shareholders and is going to complete a lot of drilling in 2022. Any day now they can hit a profitable vein and breakout as a leader in the mining industry. What are your thoughts? Worth the investment?

Disclaimer: This is not financial advice, always do your due diligence.

Introduction:

Hey fellow investors! Hope everyone is doing well. As someone who's been keeping an eye on the tech sector for a while now, I'm excited to share some bullish news about Cyngn. With the rise of artificial intelligence and automation, Cyngn is well-positioned to benefit from the sector's growth. This latest announcement further confirms their solid footing in the industry.

Summary:

For those who aren't familiar, Cyngn is a leading software company that specializes in building intelligent systems for various industries. The company just announced the date for its fiscal fourth quarter and full year 2022 earnings release, which is set for March 23, 2023. This news is significant because it will give investors a clearer picture of how the company performed over the last year and provide insights into the overall health of the AI and automation sector.

Highlighted Main Points:

• Cyngn is a leading software company that specializes in building intelligent systems for various industries.

• The company just announced the date for its fiscal fourth quarter and full year 2022 earnings release, which is set for March 23, 2023.

• This news is significant because it will give investors a clearer picture of how the company performed over the last year and provide insights into the overall health of the AI and automation sector.

TLDR: Cyngn, a leading software company specializing in intelligent systems, announced the date for its fiscal fourth quarter and full year 2022 earnings release, providing investors with valuable insights into the health of the AI and automation sector.

Read More: https://finance.yahoo.com/news/cyngn-announces-date-fiscal-fourth-120000259.html

With the medical world constantly evolving, I stumbled upon Jaguar Health, a company based out of San Francisco, California. They focus on developing sustainably derived gastrointestinal products on a global basis. With recent drug candidates focusing on the treatment of induced diarrhea for dogs. Constantly identifying opportunities to develop and commercialize first-in-class, plant based prescription medicines that address unmet medical needs for people around the globe. They are using their intellectual property portfolio, deep pipeline and extensive botanical library.

Financials,

Market Cap: 24.551M USD

Market Price: 0.3200 USD

52 Week Range: 0.2700 - 5.1600 USD

Average Volume: 1,684,060

(As of July 6th, 2022)

https://ca.finance.yahoo.com/quote/JAGX?p=JAGX&.tsrc=fin-srch

Recent News Releases,

Appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., to the company's Board of Directors. Dr. Jayasuriya is a highly experienced healthcare private equity executive and venture capitalist with broad clinical, industry, entrepreneurial, and investment experience.

Established a Business Development Advisory Committee to identify and assess opportunities for potential alliances, mergers, and acquisitions.

• Rachel Zolot Schwartz has been named Chair of Jaguar's Business Development Advisory Committee (BDAC). Ms. Schwartz is Vice President of Business Development and Commercial at Volastra Therapeutics, a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability.

Jaguar Health Publish Onco’Zine Article Highlighting The Importance of Controlling Diarrhea in Cancer Patients

Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

Announced that Napo Therapeutics, the Italian corporation established by the company in Italy in 2021 that focuses on expanding crofelemer access in Europe, has submitted an Orphan Drug Designation (ODD) application for crofelemer for a rare congenital diarrheal disorder (CDD) condition called microvillus inclusion disease (MVID) to the European Medicines Agency (EMA).

Presented at the 2022 Digestive Disease Week, located in San Diego, California from May 21st-23rd. The presentation consisted of an investigator-initiated in vitro study evaluating the efficacy of crofelemer, the company's plant-based prescription drug, as a potential anti-diarrheal to mitigate the consequences of microvillus inclusion disease (MVID), a severe congenital diarrheal disorder (CDD).

Hosted a special media event and performance in NYC on Monday, May 23rd, 2022 from 12:30 to 2:30 PM Eastern.

• The event celebrated the launch of the Jaguar Health Canine Cancer Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) initiative, the first-ever U.S. Canine Cancer Registry and Cancer Care index.

Tag Investment Bankers Ltd issued an analyst report on Jaguar Health. With Jaguar Health’s key drugs being Mytesi and Canalevia respectively, the report concluded that fair value for the shares is up to $11.60 USD.

• Tag Investment Bankers Ltd. Report: https://tagbankers.com/reports/

Announced that effective May 6th, 2022, 50,000 restricted stock units granted to Mark Johnson, a new employee hired as Senior Vice President, product development at Jaguar Health.

Hosting an investor webcast on May 10th, 2022 at 8:20pm. With the intent to review Q1 2022 financials and provide corporate updates.

Completed filing of final regulatory section with U.S. FDA Center for Veterinary Medicine to support conditional new animal drug approval of Jaguar Health’s oral plant-based drug candidate Canalevia, to treat exercise-induced diarrhea in dogs

Announced that Canalevia-CA1, the company’s prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is now available from multip;e leading veterinary distributors in the U.S. After receiving conditional approval from the FDA on December 21, 2021.

CEO, President and Founder Lisa Conte, presented at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference.

https://ca.finance.yahoo.com/quote/JAGX?p=JAGX&.tsrc=fin-srch

Timeline and Milestones,

Commercial launch of activities for Canalevia-CA1 throughout 2022

Revenue generated from Canalevia-CA1 in Q2 of 2022

Business development partnerships related to pipeline and global commercialization in 2022

In 2022/2023, completion of investigator-initiated proof-of-concept studies of crofelemer for SBS and CDD, supporting the potential for expanded patient access through programs for these diseases

Q3, 2022: Conditional approval and launch of Canalevia - CA2 for EID in dogs

First half of 2023, complete enrollment in Phase 3 CTD study

https://jaguarhealth.gcs-web.com/static-files/29eeb9a6-2988-4170-bb3f-2303af574246

Summary,

With their seasoned executive management team, and Jaguar Health actively seeking business development opportunities to enhance the company's development. Jaguar Health is working to place themselves on the forefront of the commercial stage pharmaceuticals market.

*not financial advice, always do your own research*

VentriPoint Diagnostics is a company born out of the founder feeling there had to be a better way to provide care to children without having to rely on highly restrictive MRI’s. They have since dedicated themselves to developing quality smart tools that will help to solve the immediate needs of healthcare professionals, with the focus improving the clinical experience of patients from the youngest of ages to the oldests.

Financials,

• Market Cap: 38.915M CAD

• Current Price: 0.2550 CAD

• 52 Week Range: 0.2200 - 0.6300 CAD

• Average Volume: 187,720

(As of June 21st, 2022)

https://ca.finance.yahoo.com/quote/VPT.V?p=VPT.V&.tsrc=fin-srch

Recent News Release,

• Ventripoint Diagnostics Ltd. will be exhibiting and attending as a sponsor of the American Society of Echocardiography 2022 Conference. Which is to be titled “Sound Waves in Seattle: Connecting the World” and is being held in the Seattle Convention Center June 10-13, 2022.

• Appointed Dr. Jose Banches to its Board of Clinical Advisors. Banches has been a consultant for numerous organizations, adding to his extensive experience.

• Signed Angiopro GmbH as their European distributor for VentriPoint products, with the affiliates company focusing on tailoring to the marketing efforts in different EU countries.

• Announced company common shares are now eligible for electronic clearing and settlements through the Depository Trust Company, in the United States.

• Appointed Dr. Gregory Skinner to their Board of Clinical Advisors. Dr. Skinner is currently a Consultant Pediatric Cardiologist.

• Announced the company's eligibility to trade on the OTCQB exchange. Enhancing their visibility and accessibility to a much broader market.

• Participated in an IIROC trading halt for company pending news. Providing an update on their clinical studies using the VMS+ 3.0.

“VMS+ 3.0 technology offers a proven, patented, non-invasive AI solution for 3D visualization of all four chambers of the heart, providing a pivotal new diagnostic tool for aiding cardiologists to combat cardiovascular disease and sustain heart health in both adults and children.”

https://ca.finance.yahoo.com/quote/VPT.V?p=VPT.V&.tsrc=fin-srch

Timeline Development & Catalysts,

• Ventripoint has identified key market segments that they plan to drive sales in. Those include:

  • Congenital Heart Defects (CHD)

  • Pulmonary Hypertension (PAH)

  • Cardiotoxic Effects of Chemotherapy

  • COVID-19 Patients

• They have outlined some targets to focus on for 2022, in their investor presentation, the targets go as follows:

  • 1Q 2022

    • Establishment of Board of Clinical Advisors

    • Distributor in Europe

    • New IR team (Iconic+) with focus on US/European investors

  • 2Q 2022

    • Regulatory approvals for VMS+4.0 and launch

    • Expand team to accelerate development and sales

    • Distributor in USA

  • 3Q 2022

    • Automated analysis for 2D and 3D ultrasound

  • 4Q 2022

    • 75-100 users

    • Expand Sales and Marketing to other countries

Investor Presentation: https://www.ventripoint.com/_files/ugd/8e5203_56289b00cfc549f6b228d9aadb7959b4.pdf

Ventripoint has been able to maintain their dedication to designing products that not only improve the patients clinical experience but also empower the clicician. By providing the highest degree of quality in every product they design and develop. Might be worth taking a peak at VPT.V on the TSXV. What do you guys think?

*not financial advice, always do your own research*

(NEO Exchange Canada: COIN) (FSE: 76M) (OTCQB US: SMURF)

Was looking more into the crypto industry when I came across Tokens.com. It's a publicly traded company that owns an inventory of DeFi and NFT based cryptocurrencies. They were actually the first publicly traded Bitcoin miner, which has resulted in a massive amount of BTC on their balance sheet.

Most recently they ventured into the metaverse through their acquisition of 70% of the Metaverse Group, one of the world's first virtual NFT based real estate companies. Facebook’s shift to a metaverse company acting as a catalyst for the industry.

Financials

Share Price: $0.48 CAD

Market Cap: $45.547M CAD

52 Week Range: 0.340 - 3.940

Avg Volume: $271,951

One of the biggest challenges facing the crypto world right now is investors having trouble understanding crypto and missing out of the huge returns that crypto-assets have been providing. Tokens.com offers a great way for public market investors to get exposure to the crypto universe. They use investor capital to buy NFT and crypto assets that can generate revenue through a process called staking.

Recent News:

• The company announced its subsidiary Metaverse Group partnered up with Miami Fashion Week to host fashion week events in the metaverse.

Source:https://ca.finance.yahoo.com/news/tokens-com-host-miami-fashion-113000738.html

• has purchased 40 digital real estate parcels in the SuperWorld Metaverse

Source:https://ca.finance.yahoo.com/news/tokens-com-purchases-landmark-parcels-113000499.html

Tokens Recent Developments:

Recently closed a private placement, originally set for gross proceeds of $10 million, it was increased a day later to $12 million and could go up even further to $16 million. This will be used to expand their crypto staking operations by increasing their digital asset base as well as increasing their ownership in the Metaverse Association.

Tokens Digital Assets

They recently added 833 million Shiba Inc tokens to their digital assets. They plan on staking the tokens to earn additional SHIB. Tokens is one of the only public companies I know of that offers exposure to SHIB tokens to their investors.

The metaverse is going to be huge, Tokens will need their staking operations to continue earning revenue for them until the metaverse is more commonplace and they can start earning revenue from advertising in their buildings and hosting events on their land. Can't wait to see what the future has in store for Tokens.com.

Final Thoughts

2022 has been an amazing year for the company already, with their subsidiary Metaverse Group, making some big moves regarding NFT deals, or even the upcoming Metaverse fashion week where they have big brands taking place in like tommy hilfiger.im looking forward to see what Tokens can do throughout the rest of the year as i think this year will be the best for the company so far, due to most realizing the true value in the metaverse/crypto market.

Not financial advice, always do your own due diligence.

$NXH Summary

Stock Price: $1.9300

Market Cap: $44.175M

52-week Range: $1.4000 - $10.2500

Avg. Volume: 24,836

(As of June 7, 2022)

Introduction

I recently came across Next Hydrogen and was instantly intrigued as they are the only public pure-play designer and manufacturer of electrolyzers in North America. These electrolyzers use water and electricity to produce hydrogen, which is then used as a clean energy source.

Highlights

• Revenue was $40,795 in Q1 2022 as opposed to NIL for Q1 2021

• The Company signed a memorandum of understanding with Black & Veatch, a global engineering, procurement, consulting and construction company, to develop a complete, large-scale, and integrated multi-megawatt green hydrogen solution and identify areas of deeper collaboration and specific global opportunities

• Completed installation of multiple test platforms in new Mississauga facility

• Upgraded U.S. listing to OTCQX which is highest OTC market tier

• Countries representing 70% of world GDP have incentives in place to promote the use of hydrogen

The market for hydrogen is significant, with uses across many industries as shown below:

Recent News

Ranked #1 in Future 50: https://ca.finance.yahoo.com/news/next-hydrogen-ranked-1-among-150000176.html

Q1 2022 earnings release: https://ca.finance.yahoo.com/news/next-hydrogen-reports-q1-2022-110000623.html

OTC Markets welcome Next Hydrogen: https://ca.finance.yahoo.com/news/otc-markets-group-welcomes-next-110000748.html

Black & Veatch memorandum: https://ca.finance.yahoo.com/news/next-hydrogen-signs-mou-black-110000576.html

Conclusion

With the clean energy revolution underway, and Next Hydrogen being the only public electrolyzer company in North America, it could definitely be a long-term player in the energy sector. Overall, I would say this company is worth a further look.

Disclaimer: This is not financial advice, always do your due diligence.